CTD-PAH Drug Pipeline — PatSnap Eureka
Pulmonary Hypertension in Connective Tissue Disease: Combination & Vasodilatory Pathway Approaches
CTD-PAH represents one of the most clinically challenging subtypes of WHO Group 1 pulmonary hypertension. The therapeutic landscape is bifurcating between classical vasodilatory strategies and emerging anti-remodeling biologics — explore the full patent and literature pipeline with PatSnap Eureka.
Multiple Convergent Pathways Drive CTD-PAH Pathobiology
Pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH) is driven by multiple convergent pathobiological processes: excessive pulmonary vasoconstriction, vascular remodeling driven by smooth muscle cell (SMC) and endothelial cell proliferation, inflammatory cell infiltration, and progressive right ventricular dysfunction. Systemic sclerosis, lupus, and mixed connective tissue disease are the most prevalent underlying conditions.
Key molecular targets span the endothelin-1 (ET-1) and ETA/ETB receptor axis, the prostacyclin/IP receptor pathway, the nitric oxide/sGC/cGMP axis, and the ActRII/GDF-BMP signaling cascade. The WHO Group 1 classification of CTD-PAH as a distinct subtype supports differentiated clinical trial designs and regulatory strategies.
A 2019 clinical paper from Jiangxi Provincial People's Hospital studied 88 CTD patients (43 with PAH, 45 without) and demonstrated significantly elevated asymmetrical dimethylarginine (ADMA) in CTD-PAH versus CTD-without-PAH — establishing impaired NO synthesis as a disease-specific biomarker with direct therapeutic implications. This aligns with patent-level evidence for eNOS upregulation via statins as a complementary strategy.
A 2013 academic paper from the University of Chicago explicitly articulated the gap between vasodilatory drug approval and disease-modifying outcomes, noting that epoprostenol was approved in 1995 but no drugs had yet modified the underlying pathobiologic processes of cellular proliferation, inflammation, and thrombosis — contextualizing the current innovation direction toward anti-remodeling approaches.
Vasodilatory Backbone and Emerging Anti-Remodeling Agents
Patent filings across vasodilatory small molecules, anti-proliferative agents, ActRII biologics, and endothelial dysfunction-targeting compounds define the current CTD-PAH drug landscape.
PGI2 Agonists, ERAs & PDE5 Inhibitors
Arena Pharmaceuticals discloses selexipag — a selective PGI2 receptor agonist — explicitly naming "connective tissue disease"-associated PAH as an indication. Gilead Sciences demonstrates synergistic pulmonary relaxation combining ambrisentan (selective ERA) with tadalafil (PDE5 inhibitor) in rat pulmonary artery models. Ironwood Pharmaceuticals holds active JP patents on NO-independent sGC stimulators with CTD-PAH, lupus, and collagen vascular disease as named indications.
Commercial-stage IP · Multiple jurisdictionsCDK, RTK & mTOR Inhibitors
Pfizer discloses palbociclib (CDK4/6 inhibitor) for PAH, targeting abnormal SMC and pulmonary arterial adventitial fibroblast proliferation. Actelion Pharmaceuticals discloses pyrazolopyrimidine PDGFR inhibitors designed to avoid dasatinib-class cardiotoxicity. PulmoKine discloses inhaled non-selective RTK inhibitors (PK10453) with rat MCT+PN model data showing reduction of plexiform-like occlusive lesions. Abraxas Bioscience discloses nab-rapamycin (mTOR inhibitor) for WHO FC III–IV PAH.
Preclinical to early clinical · PCT + national filingsActRII Polypeptides & GDF/BMP Antagonists
Acceleron Pharma (Bristol-Myers Squibb) is the most volumetrically active patent filer in this dataset, with pending filings spanning JP, WO, CO, CA, MX, AU, IN, KR, BR, and IL for ActRII polypeptides. The composition patent notes ActRIIA polypeptide administration reducing pulmonary vascular resistance (PVR) by ≥25–30% in preclinical models. Patient populations explicitly include CTD-associated PAH. Multiple filings describe combining ActRII with TβRII polypeptides to address both activin and TGF-β pathway dysregulation simultaneously.
≥25% PVR reduction in preclinical modelsBardoxolone Methyl & NRF2 Activation
Reata Pharmaceuticals (now AstraZeneca) holds multiple active and pending patents across WO, IL, TW, CN, and BR for bardoxolone methyl (CDDO-Me). The mechanism involves NRF2 pathway activation, reducing oxidative stress in pulmonary vascular endothelium and improving eNOS function. Scleroderma spectrum disease is referenced in cited clinical literature, directly establishing the CTD-PAH context. Multiple Reata filings cite the Badesch et al. scleroderma-PAH clinical study as prior art.
Active filings · Commercial-stage development signalsKey Molecular Targets & Assignee IP Coverage
Visualising the distribution of patent activity across molecular targets and leading assignees in the CTD-PAH drug development landscape.
Leading Assignees: Jurisdiction Coverage in CTD-PAH
Acceleron/BMS holds the broadest multi-jurisdiction IP position with 10+ national filings for ActRII polypeptides across PAH and CTD-PAH indications.
Combination Strategy Coverage in Patent Record
Seven distinct combination approaches are documented across the CTD-PAH patent landscape, spanning vasodilatory, anti-remodeling, and anti-inflammatory axes.
Seven Distinct Combination Strategies in the CTD-PAH Patent Record
ERA + PDE5i, PDE4i + statin, TPH inhibitor + prostacyclin, and ActRII + TβRII combinations are all documented — with IP implications for standard-of-care plus investigational combinations.
Novel Targets Beyond Established Vasodilatory Axes
Academic institutions and emerging biotech are filing on novel mechanisms — from miRNA regulation to TSPO ligands — representing the next wave of CTD-PAH innovation.
BMPR2/FHIT Restoration via Enzastaurin
Stanford University demonstrates enzastaurin prevention and reversal of pulmonary hypertension in animal models via FHIT and BMPR2 upregulation, with RVSP elevation, right ventricular hypertrophy, and vascular muscularization as measurable endpoints — converging with Acceleron's ActRII approach on the BMP pathway as central to PAH pathobiology.
Integrin α5β1 Inhibition (Morphic Therapeutic)
Morphic Therapeutic discloses integrin α5β1 inhibitors for PAH and right ventricular failure. The mechanistic rationale: fibronectin-integrin signaling promotes PASMC proliferation and resistance to apoptosis — contributing to vascular remodeling. Evidence is patent-based; stage appears preclinical.
TSPO Ligands & Metabolic Reprogramming
Imperial College Innovations discloses translocator protein (TSPO) ligands targeting pulmonary endothelial cell dysfunction and the Warburg-like metabolic shift (oxidative phosphorylation to glycolysis) observed in PAH vascular cells — a mechanism with growing mechanistic support in the academic literature.
Biomarker-Driven Stratification: ADMA, CCL21 & Cytokine Panels
Novartis discloses CCL21 as a pharmacodynamic biomarker for anti-remodeling efficacy — upregulated in PH, downregulated following anti-remodeling therapy. INSERM discloses a 3-cytokine panel (β-NGF, CXCL9, TRAIL) as PAH severity and mortality predictors. ADMA is clinically validated as a CTD-PAH-specific biomarker in 88 patients. Companion diagnostic development linked to anti-remodeling agents represents a gap with commercial and regulatory value.
From Patent Claims to Clinical Endpoints: Key Translational Evidence
Among retrieved results, the strongest clinical signals are concentrated in sotatercept (ActRII polypeptide), bardoxolone methyl, and selexipag. The Acceleron ActRII Japanese filing explicitly describes clinical pharmacodynamic endpoints — reduction in PVR, increase in 6-minute walk distance (6MWD), decrease in NT-proBNP levels, WHO Functional Class progression prevention, and improved right ventricular function — in patients receiving the polypeptide at doses of 1.0–2.0 mg/kg.
Multiple Reata Pharmaceuticals filings cite the Badesch et al. scleroderma-PAH clinical study as prior art, situating the endothelial dysfunction indication squarely in the CTD-PAH context. Active filings across multiple jurisdictions suggest commercial-stage development for bardoxolone methyl.
Genentech's vixarelimab (anti-OSM receptor β antibody) filing references Phase 2 clinical studies (NCT03816838; NCT03858634) in prurigo nodularis and atopic dermatitis, with ILD/SSc-ILD positioned as the target indication for pulmonary fibrotic disease — generating translational relevance for CTD-PAH given SSc-ILD is a direct antecedent condition.
The NIH-registered clinical trial infrastructure and the EMA orphan disease framework both support differentiated regulatory pathways for CTD-PAH as a distinct subpopulation — a strategy explicitly supported by the filings from Acceleron, Arena, Ironwood, and Reata, all of which enumerate connective tissue disease-associated PAH as a named indication.
Map the Full Clinical & Translational CTD-PAH Landscape
Use PatSnap Eureka to cross-reference patent claims with clinical trial registrations and published literature.
What the CTD-PAH Patent Landscape Means for Drug Developers
Anti-remodeling is the dominant emerging IP theme. IP strategists, R&D teams, and regulatory affairs professionals should assess the following signals from the patent record.
Acceleron/BMS Holds Dominant GDF-BMP Position
The breadth of pending national phase filings across 10+ jurisdictions for sotatercept and related ActRII polypeptides creates a strong IP enclosure around the BMP/activin pathway in PH-ILD and CTD-PAH. Competitors will need to establish freedom-to-operate around TβRII combination approaches or alternative structural ActRII variants.
10+ jurisdictions · Multiple distinct familiesCTD-PAH Explicitly Named in Key Filings
Filings from Acceleron, Arena, Ironwood, and Reata all explicitly enumerate connective tissue disease-associated PAH as an indication. This supports differentiated clinical trial designs and potential regulatory pathways for CTD-PAH as a distinct orphan or rare disease subpopulation — a significant commercial and regulatory opportunity aligned with life sciences IP strategy.
Orphan/rare disease pathway opportunityCombination Patents May Create Blocking Positions
ERA + PDE5i, PDE4i + statin, TPH inhibitor + prostacyclin, and ActRII + TβRII combinations are all covered in the patent record. IP strategists should assess whether combination patent filings create blocking positions around standard-of-care plus investigational combinations — particularly for programs planning to add anti-remodeling agents to existing vasodilator backbones.
7 distinct combination strategies documentedBiomarker-Driven Stratification: Underserved IP Space
Retrieved results include ADMA (clinical; CTD-PAH-specific), CCL21 (Novartis biomarker patent), NT-proBNP response, and a 3-cytokine panel (β-NGF, CXCL9, TRAIL from INSERM) as PAH severity and mortality predictors. Companion diagnostic development linked to anti-remodeling agents represents a gap with commercial and regulatory value for CTD-PAH drug development programs. Explore the PatSnap customer success stories for biomarker IP strategy examples.
ADMA · CCL21 · β-NGF/CXCL9/TRAIL panelCTD-PAH Drug Pipeline — Key Questions Answered
Retrieved results identify three established vasodilatory drug classes as the backbone of CTD-PAH pharmacotherapy: prostacyclin/IP receptor agonists (e.g. selexipag), endothelin receptor antagonists (ERAs, e.g. ambrisentan), and PDE5 inhibitors (e.g. tadalafil). Emerging anti-remodeling modalities include ActRII biologics, CDK inhibitors, PDGFR inhibitors, mTOR inhibitors, and sGC stimulators.
Acceleron Pharma (Bristol-Myers Squibb) is the most volumetrically represented assignee in the dataset, with pending filings spanning JP, WO, CO, CA, MX, AU, IN, KR, BR, and IL for ActRII polypeptides. Multiple distinct families address PAH, PH-ILD, post-capillary PH, and CTD-associated forms, reflecting a broad IP enclosure strategy around the GDF/BMP pathway.
ERA + PDE5i, PDE4i + statin, TPH inhibitor + prostacyclin, and ActRII + TβRII combinations are all covered in the patent record. The Gilead ambrisentan + tadalafil filing explicitly demonstrates synergistic relaxation of pulmonary vasoconstriction, and Lexicon Pharmaceuticals discloses tryptophan hydroxylase inhibitor + prostacyclin combination for pulmonary hypertension treatment.
A 2019 clinical paper from Jiangxi Provincial People's Hospital studied 88 CTD patients (43 with PAH, 45 without) using echocardiography and ELISA-measured ADMA. The authors report ADMA as significantly elevated in CTD-PAH versus CTD-non-PAH, with correlation to pulmonary function parameters. This establishes impaired NO synthesis as a disease-specific biomarker with therapeutic implications.
A 2013 academic paper from the University of Chicago explicitly articulates the gap between vasodilatory drug approval and disease-modifying outcomes, noting that epoprostenol was approved in 1995 but no drugs had yet modified the underlying pathobiologic processes of cellular proliferation, inflammation, and thrombosis. This contextualizes the current innovation direction toward anti-remodeling approaches including ActRII biologics, CDK inhibitors, PDGFR inhibitors, and mTOR inhibitors.
The Japanese PAH-specific filing explicitly describes clinical pharmacodynamic endpoints — reduction in PVR, increase in 6-minute walk distance (6MWD), decrease in NT-proBNP levels, WHO Functional Class progression prevention, and improved right ventricular function — in patients receiving the polypeptide at doses of 1.0–2.0 mg/kg. The CTD-PAH patient population is explicitly named within the composition patent (JP active).
Still have questions? Let PatSnap Eureka search the CTD-PAH patent and literature record for you.
Ask Eureka About CTD-PAHAccelerate Your CTD-PAH Drug Development Intelligence
Join 18,000+ innovators already using PatSnap Eureka to track pipelines, map IP landscapes, and identify combination strategy opportunities across rare pulmonary diseases.
References
- Compositions and methods for treating pulmonary hypertension — Gilead Sciences, Inc., 2014, JP [Patent]
- Treatment of conditions associated with the PGI2 receptor — Arena Pharmaceuticals, Inc., 2017, JP [Patent]
- sGC stimulant — Ironwood Pharmaceuticals, Inc., 2013, JP [Patent]
- sGC stimulant — Ironwood Pharmaceuticals, Inc., 2013, JP [Patent]
- Compositions and methods for treating pulmonary hypertension — Acceleron Pharma, Inc., 2019, JP [Patent]
- ACTRII Proteins for the Treatment of Pulmonary Arterial Hypertension (PAH) — Acceleron Pharma, Inc., 2023, JP [Patent]
- Actrii proteins and uses thereof — Acceleron Pharma, Inc., 2022, WO [Patent]
- Pyrazolopyrimidines and their use as PDGFR inhibitors — Actelion Pharmaceuticals Ltd., 2024, JP [Patent]
- Clinical Value of Asymmetrical Dimethylarginine Detection in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension — Department of Rheumatology, Jiangxi Provincial People's Hospital, 2019 [Paper]
- Treprostinil therapy for interstitial lung disease and asthma — United Therapeutics Corporation, 2010, CN [Patent]
- Roflumilast for treatment of pulmonary hypertension — Takeda GmbH (formerly Nycomed GmbH), 2013, JP [Patent]
- Methods of using PDE4 modulators for treating pulmonary hypertension — Celgene Corporation, 2007, JP [Patent]
- Anti-proliferative agents for treating PAH — Pfizer Inc., 2019, CN [Patent]
- Anti-proliferative agents for treating PAH — Pfizer Inc., 2018, JP [Patent]
- Spray-dried formulations — PulmoKine, Inc., 2016, CN [Patent]
- Methods and compositions for treating pulmonary hypertension — Abraxas Bioscience LLC, 2024, JP [Patent]
- Actrii proteins and uses thereof — Acceleron Pharma, Inc., 2022, WO [Patent]
- Methods of treating and preventing endothelial dysfunction using bardoxolone methyl — Reata Pharmaceuticals, Inc., 2015, WO [Patent]
- Methods of treating and preventing endothelial dysfunction using bardoxolone methyl — Reata Pharmaceuticals Holdings LLC, 2021, IL [Patent]
- Fusion protein of ETA antibody and BNP, pharmaceutical composition thereof and application — Hongyun Huaning (Hangzhou) Biomedical [Patent]
- WHO Group 1 Pulmonary Hypertension Classification — World Health Organization
- NIH Clinical Trials Registry — CTD-PAH Studies — National Institutes of Health
- EMA Orphan Disease Designation Framework — European Medicines Agency
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.